116 related articles for article (PubMed ID: 20734401)
41. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
[TBL] [Abstract][Full Text] [Related]
42. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.
Kim H; Sohn HJ; Kim S; Lee JS; Kim WK; Suh C
Bone Marrow Transplant; 2006 Jun; 37(11):1037-42. PubMed ID: 16708062
[TBL] [Abstract][Full Text] [Related]
43. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
44. Predicting and facilitating survival of pediatric cancer patients: the ALC story.
Anderson P
Pediatr Blood Cancer; 2010 Dec; 55(6):1041-2. PubMed ID: 20672372
[No Abstract] [Full Text] [Related]
45. Early Lymphocyte Recovery and Outcome in Osteosarcoma.
Lee L; Fei L; Pope J; Wagner LM
J Pediatr Hematol Oncol; 2017 Apr; 39(3):179-183. PubMed ID: 27879546
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma.
Koh YW; Kang HJ; Park C; Yoon DH; Kim S; Suh C; Kim JE; Kim CW; Huh J
Am J Clin Pathol; 2012 Dec; 138(6):846-54. PubMed ID: 23161719
[TBL] [Abstract][Full Text] [Related]
47. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma.
Zhou Y; Liu B; Wang M; Ni J
Pediatr Blood Cancer; 2014 Apr; 61(4):612-7. PubMed ID: 24123836
[TBL] [Abstract][Full Text] [Related]
48. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas.
Vasquez L; León E; Beltran B; Maza I; Oscanoa M; Geronimo J
J Pediatr Hematol Oncol; 2017 Oct; 39(7):538-546. PubMed ID: 28697168
[TBL] [Abstract][Full Text] [Related]
49. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics.
Kikuta K; Tochigi N; Saito S; Shimoda T; Morioka H; Toyama Y; Hosono A; Suehara Y; Beppu Y; Kawai A; Hirohashi S; Kondo T
Proteomics Clin Appl; 2010 May; 4(5):560-7. PubMed ID: 21137073
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors and treatment of relapsed osteosarcoma: A monocentric Tunisian retrospective study.
Ben Kridis W; Ennouri S; Khmiri S; Keskes H; Daoud J; Khanfir A
Arch Pediatr; 2022 May; 29(4):287-291. PubMed ID: 35304030
[TBL] [Abstract][Full Text] [Related]
51. Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.
Vánky F; Klein E; Willems J; Böök K; Ivert T; Péterffy A; Nilsonne U; Kreicbergs A; Aparisi T
Cancer Immunol Immunother; 1986; 21(1):69-76. PubMed ID: 3455878
[TBL] [Abstract][Full Text] [Related]
52. The role of interferons in the treatment of osteosarcoma.
Whelan J; Patterson D; Perisoglou M; Bielack S; Marina N; Smeland S; Bernstein M
Pediatr Blood Cancer; 2010 Mar; 54(3):350-4. PubMed ID: 19902521
[TBL] [Abstract][Full Text] [Related]
53. Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients.
Buddingh EP; Ruslan SE; Berghuis D; Gelderblom H; Anninga JK; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Cancer Immunol Immunother; 2012 Jun; 61(6):941-7. PubMed ID: 22402907
[TBL] [Abstract][Full Text] [Related]
54. Neuroendocrine-immune surveillance of osteosarcoma: emerging hypothesis.
Prolo P; Chiappelli F; Bernard G; Fiala M; Ibarra A; Sartori ML; Dovio A; Angeli A
J Dent Res; 2003 Jun; 82(6):417-21. PubMed ID: 12766191
[TBL] [Abstract][Full Text] [Related]
55. Can historical controls be used in current clinical trials in osteosarcoma. Analysis of Prognostic factors.
Broström LA; Aparisi T; Ingimarsson S; Lagergren C; Nilsonne U; Strander H; Söderberg G
Int J Radiat Oncol Biol Phys; 1980 Dec; 6(12):1711-5. PubMed ID: 6165708
[No Abstract] [Full Text] [Related]
56. Impaired lymphocyte responsiveness in osteosarcoma.
Twomey PL; Chretien PB
J Surg Res; 1975 May; 18(5):551-4. PubMed ID: 1055278
[No Abstract] [Full Text] [Related]
57. Lymphocyte count in peripheral blood is a sensitive tool in pretreatment assessment of patients with urological cancer.
Yakovlev P; Klyushin D
Exp Oncol; 2018 Jun; 40(2):119-123. PubMed ID: 29949533
[TBL] [Abstract][Full Text] [Related]
58. Immunocompetence of lymphocytes from osteosarcoma patients.
McMaster JH; Weinert CR; Dickens DR
Lancet; 1973 Apr; 1(7806):781-2. PubMed ID: 4120769
[No Abstract] [Full Text] [Related]
59. T cells, precocious aging, and familial neoplasia.
Fudenberg HH; Schuman SH; Goust JM; Jorgenson R
Gerontology; 1978; 24(4):266-75. PubMed ID: 304823
[TBL] [Abstract][Full Text] [Related]
60. Treatment of secondary osteosarcoma in a pediatric Hodgkin lymphoma survivor: Overcoming toxicity challenges.
Aquino-López A; Wang LL; Flores RJ
Pediatr Blood Cancer; 2021 Dec; 68(12):e29269. PubMed ID: 34383364
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
